Latest Breaking News On - Sidi chen - Page 1 : vimarsana.com

In a promising form of immunotherapy known as CAR T-cell (chimeric antigen receptor) therapy, the patient’s T cells are engineered to better recognize and attack antigens on the surface of cancer cells. In treatments currently approved for use in battling lymphoma and leukemia, however, the therapy has a drawback: Amidst the cancer-killing frenzy, many engineered T cells become tainted with the remnants of cancer antigens, which causes them to turn on other T cells. This eventually depletes the body of cancer-fighting cells and opens the door for a recurrence of cancer. A new Yale study, however, has identified a way to tame the self-destructive tendencies of these killer T cells. Simply fusing a molecular tail onto the engineered T cells used in therapy, researchers say, can inhibit their proclivity to attack each other. The study was published July 27 in the journal Nature Immunology.

Hanbing caoSidi chenXiaoyu zhouYale stem cell centerYale school of medicineSystems biology instituteYale centerNational institutes of healthUs department of defenseYale cancer centerNew havenYale schoolBiomedical data scienceCancer systems biologyNational institutes